13D Filing: Culpepper Peter R and Provectus Biopharmaceuticals Inc. (NYSEMKT:PVCT)

previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following...... (read more)